myotonic dystrophy Type 1

Stop sign
Biotech

PepGen hit with partial hold, analyst blames 'understaffed FDA'

The FDA put a partial hold on PepGen’s phase 2 muscle wasting trial after reviewing preclinical data, continuing the stop-start advance of the asset.
Nick Paul Taylor Mar 5, 2026 5:45am
Completing steps towards success checkmark on cubes symbolizing progress

Sarepta shares safety update on DM1 RNA med

Nov 24, 2025 4:00pm
plan B fail reroute road path trail miss

PepGen ends all DMD work after phase 2 trial falls flat

May 28, 2025 5:30pm
Desert sand dunes

RNA-targeting drug relaxes muscles in myotonic dystrophy mice

Dec 4, 2024 7:00am
Novartis

Novartis signs $1.1B deal for muscular dystrophy biotech

Nov 21, 2024 8:19am
steps race jump stairs climb

PepGen gains a little pep in its step as FDA clears trial hold

Oct 12, 2023 7:00am